Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology

Neuropsychopharmacology

Volumn 28, Issue 8, 2003, Pages 1400-1411

  Shapiro, David A ^a   Renock, Sean ^a   Arrington, Elaine ^b   Chiodo, Louis A ^c   Liu, Li Xin ^c   Sibley, David R ^d   Roth, Bryan L ^a   Mailman, Richard ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Aripiprazole; Atypical antipsychotic; Partial agonist; Receptor pharmacology; Schizophrenia

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CARRIER PROTEIN; DOPAMINE 2 RECEPTOR; DOPAMINE 2L RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; G PROTEIN COUPLED RECEPTOR; HISTAMINE H1 RECEPTOR; HISTAMINE H3 RECEPTOR; PARTIAL AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 7 RECEPTOR; UNCLASSIFIED DRUG; CYCLIC AMP; DOPAMINE RECEPTOR; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; POTASSIUM CHANNEL; QUINOLONE DERIVATIVE; SEROTONIN RECEPTOR;

AGONIST; ARTICLE; BINDING AFFINITY; CELL TYPE; DATA ANALYSIS; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HYPOTHESIS; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; BIOSYNTHESIS; DOSE RESPONSE; PHYSIOLOGY;

ANTIPSYCHOTIC AGENTS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PIPERAZINES; POTASSIUM CHANNELS; QUINOLONES; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN;

EID: 0042887023     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300203     Document Type: Article

References (67)

1. Arnt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18: 63-101.
2. Bhatnagar A, Willins DL, Gray JA, Woods J, Benovic JL, Roth BL (2001). The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis. J Biol Chem 276: 8269-8277.
3. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T et al (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302: 381-389.
4. Choudhary MS, Craigo S, Roth BL (1992). Identification of receptor domains that modify ligand binding to 5-hydroxytryptamine2 and 5-hydroxytryptamine1c serotonin receptors. Mol Pharmacol 42: 627-633.
5. Creese I, Burt DR, Snyder SH (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481-483.
6. Egan C, Grinde E, Dupre A, Roth BL, Hake M, Teitler M et al (2000). Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse 35: 144-150.
7. Ellenbroek BA, Prinssen EP, Cools AR (1994). The role of serotonin receptor subtypes in the behavioural effects of neuroleptic drugs. A paw test study in rats. Eur J Neurosci 6: 1-8.
8. Feenstra RW, de Moes J, Hofma JJ, Kling H, Kuipers W, Long SK et al (2001). New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities. Bioorg Med Chem Lett 11: 2345-2349.
9. Filtz TM, Artymyshyn RP, Guan W, Molinoff PB (1993). Paradoxical regulation of dopamine receptors in transfected 293 cells. Mol Pharmacol 44: 371-379.
10. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA et al (2000). Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57: 75-81.
11. Ghaemi SN, Cherry EL, Katzow JA, Goodwin FK (2000). Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disord 2: 196-199.
12. Goodnick PJ, Jerry JM (2002). Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 3: 1773-1781.
13. Goodnick PJ, Rodriguez L, Santana O (2002). Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 3: 1381-1391.
14. Gray JA, Sheffler DJ, Bhatnagar A, Woods JA, Hufeisen SJ, Benovic JL et al (2001). Cell-type specific effects of endocytosis inhibitors on 5-hydroxytryptamine(2A) receptor desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic kidney 293 cells. Mol Pharmacol 60: 1020-1030.
15. Hamel E (1999). The biology of serotonin receptors: focus on migraine pathophysiology and treatment. Can J Neurol Sci 26(Suppl 3): S2-S6.
16. Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H et al (1997). Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 321: 105-111.
17. 1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 277: 137-143.
18. Johnson KW, Phebus LA, Cohen ML (1998). Serotonin in migraine: theories, animal models and emerging therapies. Prog Drug Res 51: 219-244.
19. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-796.
20. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL et al (2002). Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63: 763-771.
21. Kenakin T (1995). Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16: 232-238.
22. Kilts JD, Connery HS, Arrington EG, Lewis MM, Lawler CP, Oxford GS et al (2002). Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther 301: 1179-1189.
23. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P et al (2003). H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28(3): 519-526.
24. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA et al (1999). Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20: 612-627.
25. Liebman JM, Gerhardt SC, Gerber R (1989). Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction. Psychopharmacology 97: 456-461.
26. Liu LX, Burgess LH, Gonzalez AM, Sibley DR, Chiodo LA (1999). D2S, D2L, D3, and D4 dopamine receptors couple to a voltage-dependent potassium current in N18TG2 x mesencephalon hybrid cell (MES-23.5) via distinct G proteins. 31: 108-118.
27. Martin JR, Bos M, Jenck F, Moreau J, Mutel V, Sleight AJ et al (1998). 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286: 913-924.
28. Martin-Ruiz R, Puig MV, Celada P, Shapiro DA, Roth BL, Mengod G et al (2001). Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci 21: 9856-9866.
29. Max SI, Monsma Jr FJ, Sibley DR (1995). Agonist-induced desensitization of 5-HT6 serotonin receptor-coupled adenylyl cyclase in stably transfected HEK-293 cells. J Serotonin Res 2: 101-116.
30. Meltzer HY, Matsubara S, Lee JC (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251: 238-246.
31. Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233-255.
32. Milan N, Brussels J, Milan G (1992). New generation of antipsychotic drugs: novel mechanisms of action. Workshop, Monte Carlo, March 16-18, 1992. pp 1-14.
33. Monsma Jr FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR (1993). Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 43: 320-327.
34. Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR et al (2002). Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 301: 1166-1178.
35. Munson PJ, Rodbard D (1980). LIGAND: a versatile, computerized approach for characterization of ligand-binding systems. Anal Biochem 107: 220-239.
36. Narendran R, Young CM, Valenti AM, Pristach CA, Pato MT, Grace JJ (2001). Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. J Clin Psychiatry 62: 509-516.
37. Neve KA (1991). Regulation of dopamine D2 receptors by sodium and pH. Mol Pharmacol 39: 570-578.
38. Neve KA, Cox BA, Henningsen RA, Spanoyannis A, Neve RL (1991). Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase. Mol Pharmacol 39: 733-739.
39. Neve KA, Cumbay MG, Thompson KR, Yang R, Buck DC, Watts VJ et al (2001). Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. Mol Pharmacol 60: 373-381.
40. Nordstedt C, Fredholm BB (1990). A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. Anal Biochem 189: 231-234.
41. 1H)-quinolinone derivatives. J Med Chem 41: 658-667.
42. Rauser L, Savage JE, Meltzer HY, Roth BL (2001). Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther 299: 83-89.
43. Richelson E (1999). Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 60: 5-14.
44. Roth BL (1994). Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry 6: 67-78.
45. Roth BL (2000). Neuronal signal transduction pathways: wasteland or the promised land? Sci STKE 2000(45): PE1.
46. Roth BL, Ciaranello RD, Meltzer HY (1992). Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 260: 1361-1365.
47. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma Jr FJ, Shen Y et al (1994). Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268: 1403-1410.
48. Roth BL, Meltzer H, Khan N (1998). Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors. In: August JT, Anders MW, Murad F, Coyle JT (eds). Advances in Pharmacology, Vol 42 Academic Press: San Diego. pp 482-485.
49. Roth BL, Nakaki T, Chuang DM, Costa E (1986). 5-Hydroxytryptamine2 receptors coupled to phospholipase C in rat aorta: modulation of phosphoinositide turnover by phorbol ester. J Pharmacol Exp Ther 238: 480-485.
50. Roth BL, Sheffler D, Potkin S (In Press). Atypical antipsychotic drug actions: unitary or multiple mechanisms for 'Atypicality'? Clin Neurosci Res.
51. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY (1995). D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl) 120: 365-368.
52. 2A receptors in atypical antipsychotic drug actions. Neuroscientist 5: 254-262.
53. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ et al (2000). Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102: 2836-2841.
54. Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF (2001). Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry 62: 273-281.
55. Shapiro DA, Kristiansen K, Kroeze WK, Roth BL (2000). Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol Pharmacol 58: 877-886.
56. Shen Y, Monsma Jr FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley DR (1993). Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem 268: 18200-18204.
57. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146-151.
58. Stanton T, Bolden-Watson C, Cusack B, Richelson E (1993). Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem Pharmacol 45: 2352-2354.
59. Tamminga CA (2002). Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109: 411-420.
60. Tsai Y, Dukat M, Slassi A, MacLean N, Demchyshyn L, Savage JE et al (2000). N1-(Benzenesulfonyl)tryptamines as novel 5-HT6 antagonistst. Bioorg Med Chem Lett 10: 2295-2299.
61. Van Tol HHM, Bunzow JR, Guan HC, Sunahara H-C, Seeman P, Niznik HB et al (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-614.
62. Vickers SP, Clifton PG, Dourish CT, Tecott LH (1999). Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice. Psychopharmacology (Berl) 143: 309-314.
63. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J et al (1999). Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60: 358-363.
64. Worrel JA, Marken PA, Beckman SE, Ruehter VL (2000). Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 57: 238-255.
65. Wyatt RJ, Henter I, Leary MC, Taylor E (1995). An economic evaluation of schizophrenia - 1991. Soc Psychiatry Psychiatr Epidemiol 30: 196-205.
66. Zeng XP, Le F, Richelson E (1997). Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol 321: 349-354.
67. Zhang LJ, Lachowicz JE, Sibley DR (1994). The D2S and D2L dopamine receptor isoforms are differentially regulated in Chinese hamster ovary cells. Mol Pharmacol 45: 878-889.